- Home
- LMB vs AUPH Comparison
LMB vs AUPH Comparison
Compare LMB & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- AUPH
- Stock Information
- Founded
- LMB 1901
- AUPH 1993
- Country
- LMB United States
- AUPH Canada
- Employees
- LMB N/A
- AUPH N/A
- Industry
- LMB Engineering & Construction
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- AUPH Health Care
- Exchange
- LMB Nasdaq
- AUPH Nasdaq
- Market Cap
- LMB 1.2B
- AUPH 1.4B
- IPO Year
- LMB 2014
- AUPH 1999
- Fundamental
- Price
- LMB $98.24
- AUPH $11.47
- Analyst Decision
- LMB Strong Buy
- AUPH Strong Buy
- Analyst Count
- LMB 3
- AUPH 2
- Target Price
- LMB $130.33
- AUPH $13.00
- AVG Volume (30 Days)
- LMB 214.7K
- AUPH 1.8M
- Earning Date
- LMB 11-04-2025
- AUPH 11-06-2025
- Dividend Yield
- LMB N/A
- AUPH N/A
- EPS Growth
- LMB 35.95
- AUPH N/A
- EPS
- LMB 2.92
- AUPH 0.42
- Revenue
- LMB $552,919,000.00
- AUPH $260,111,000.00
- Revenue This Year
- LMB $28.57
- AUPH $17.33
- Revenue Next Year
- LMB $14.48
- AUPH $14.31
- P/E Ratio
- LMB $33.55
- AUPH $26.72
- Revenue Growth
- LMB 8.06
- AUPH 25.59
- 52 Week Low
- LMB $63.02
- AUPH $6.55
- 52 Week High
- LMB $154.05
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- LMB 47.03
- AUPH 45.30
- Support Level
- LMB $89.43
- AUPH $10.92
- Resistance Level
- LMB $98.50
- AUPH $11.84
- Average True Range (ATR)
- LMB 4.18
- AUPH 0.61
- MACD
- LMB 1.15
- AUPH -0.08
- Stochastic Oscillator
- LMB 82.56
- AUPH 34.06
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.